Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$VRTX recent news/filings
bullish
## source: finance.yahoo.com
Thu, 14 Aug 2014 18:42:20 GMT ~ SEC probing Valeant, Ackman's hostile Allergan bid - WSJ
[Reuters] - A hostile takeover bid by billionaire investor William Ackman and Valeant Pharmaceuticals International Inc to acquire Allergan Inc is being investigated by federal regulators for possible violations of securities laws, the Wall Street Journal reported, citing people familiar with the matter. The Securities and Exchange Commission civil probe was focused on potential breaches of insider trading laws, the Journal reported, citing one of the people. Earlier this month, Botox maker Allergan accused Valeant and Ackman of violating securities laws by using insider information as they prepared a takeover bid for the drug company.
read full: http://finance.yahoo.com/news/sec-probing-valeant-ackmans-hostile-184220263.html
*********************************************************
Wed, 13 Aug 2014 19:54:44 GMT ~ Vertex leads S&P 500, King drops on outlook
read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=D058BDD8-2256-11E4-9C1E-00212803FAD6&siteid=yhoof2
*********************************************************
Wed, 13 Aug 2014 18:42:21 GMT ~ Vertex to end sales of hepatitis C drug Incivek
read full: http://finance.yahoo.com/news/vertex-end-sales-hepatitis-c-184221942.html
*********************************************************
Wed, 13 Aug 2014 13:58:54 GMT ~ Shares Rise, as Biotech Gains Offset Listless Retail Sales
read full: http://www.nytimes.com/2014/08/14/business/daily-stock-market-activity.html?partner=yahoofinance
*********************************************************
Tue, 12 Aug 2014 15:00:38 GMT ~ From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate
read full: http://blogs.wsj.com/pharmalot/2014/08/12/from-riches-to-rags-vertex-discontinues-incivek-as-sales-evaporate/?mod=yahoo_hs
*********************************************************
$VRTX charts
basic chart ## source: stockcharts.com
basic chart ## source: eoddata.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$VRTX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/VRTX/company-info
Ticker: $VRTX
OTC Market Place: Not Available
CIK code: 0000875320
Company name: Vertex Pharmaceuticals Inc.
Company website: http://www.vpharm.com
Incorporated In: MA, USA
$VRTX share structure
## source: otcmarkets.com
Market Value: $21,636,849,719 a/o Aug 15, 2014
Shares Outstanding: 238,081,533 a/o Jul 25, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$VRTX extra dd links
Company name: Vertex Pharmaceuticals Inc.
Company website: http://www.vpharm.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=VRTX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=VRTX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=VRTX+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/news - http://finance.yahoo.com/q/h?s=VRTX+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/VRTX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=VRTX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/VRTX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Vertex+Pharmaceuticals+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Vertex+Pharmaceuticals+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Vertex+Pharmaceuticals+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.vpharm.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.vpharm.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.vpharm.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/VRTX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=VRTX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=VRTX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=VRTX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=VRTX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=VRTX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=VRTX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=VRTX+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/VRTX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=VRTX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/VRTX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=VRTX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/VRTX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/VRTX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/VRTX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=VRTX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=VRTX
$VRTX DD Notes ~ http://www.ddnotesmaker.com/VRTX
this stock should pay divy's
$VRTX Current Trading Levels Reflect Appropriate Value For VRTX Shares, Says H.C. Wainwright http://www.smarteranalyst.com/2014/07/24/current-trading-levels-reflect-appropriate-value-for-vrtx-shares-says-h-c-wainwright/
$VRTX recent news/filings
bullish
## source: finance.yahoo.com
Tue, 22 Jul 2014 21:44:09 GMT ~ SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Vertex Pharmaceuticals Incorporated To Contact The Firm Before The Lead Plaintiff Deadline In Class Action Lawsuit -- VRTX
[GlobeNewswire] - STEVENSON, Md. -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District ...
read full: http://finance.yahoo.com/news/shareholder-alert-brower-piven-encourages-214409376.html
*********************************************************
Fri, 18 Jul 2014 15:34:00 GMT ~ Sales Tax Compliance Concerns Loom Large, But Does Automation Help?
[at Forbes] - Many businesses may think they have taken the appropriate steps to be prepared for a sales and use tax audit, until the notice of audit arrives.
read full: http://www.forbes.com/sites/taxanalysts/2014/07/18/sales-tax-compliance-concerns-loom-large-but-does-automation-help/?partner=yahootix
*********************************************************
Thu, 17 Jul 2014 13:22:59 GMT ~ [$$] Costly Vertex Drug Is Denied, and Medicaid Patients Sue
[at The Wall Street Journal] - Vertex Pharmaceuticals' $300,000-a-year cystic-fibrosis drug has sparked a battle in Arkansas, illustrating the dilemma faced by cash-strapped government insurance programs.
read full: http://online.wsj.com/articles/costly-drug-vertex-is-denied-and-medicaid-patients-sue-1405564205?ru=yahoo?mod=yahoo_itp
*********************************************************
Wed, 16 Jul 2014 12:49:41 GMT ~ Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data
read full: http://finance.yahoo.com/news/biotech-stock-roundup-abbvie-woos-124941477.html
*********************************************************
Tue, 15 Jul 2014 17:32:26 GMT ~ SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX
[GlobeNewswire] - NEW YORK -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals ...
read full: http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-173226066.html
*********************************************************
$VRTX charts
basic chart ## source: stockcharts.com
basic chart ## source: eoddata.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$VRTX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/VRTX/company-info
Ticker: $VRTX
OTC Market Place: Not Available
CIK code: 0000875320
Company name: Vertex Pharmaceuticals Inc.
Company website: http://www.vpharm.com
Incorporated In: MA, USA
$VRTX share structure
## source: otcmarkets.com
Market Value: $23,085,634,498 a/o Jul 22, 2014
Shares Outstanding: 236,194,337 a/o Apr 25, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$VRTX extra dd links
Company name: Vertex Pharmaceuticals Inc.
Company website: http://www.vpharm.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=VRTX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=VRTX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=VRTX+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/news - http://finance.yahoo.com/q/h?s=VRTX+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/VRTX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=VRTX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/VRTX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Vertex+Pharmaceuticals+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Vertex+Pharmaceuticals+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Vertex+Pharmaceuticals+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.vpharm.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.vpharm.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.vpharm.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/VRTX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=VRTX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=VRTX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=VRTX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=VRTX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=VRTX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=VRTX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=VRTX+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/VRTX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=VRTX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/VRTX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=VRTX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/VRTX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/VRTX/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/VRTX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/VRTX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/VRTX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=VRTX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=VRTX
$VRTX DD Notes ~ http://www.ddnotesmaker.com/VRTX
jkflb
To make up for your loss? Lol
How did you manage to cover your short position at that price today?
Toofuzzy
If he is short from last week his ass is hurting really bad today.
VRTX $102.80 ON BIG NEWS
Vertex Pharmaceuticals Incorporated : Patent Issued for Protein Kinase Inhibitors
01/08/2014 | 05:34pm US/EasternRecommend:
0
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A patent by the inventors Charrier, Jean-Damien (Abingdon, GB); Durrant, Steve (Abingdon, GB), filed on August 24, 2012, was published online on December 31, 2013, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents (see also Biotechnology Companies).
Patent number 8618106 is assigned to Vertex Pharmaceuticals Incorporated (Cambridge, MA).
The following quote was obtained by the news editors from the background information supplied by the inventors: "The search for new therapeutic agents has been greatly aided in recent years by a better understanding of the structure of enzymes and other biomolecules associated with diseases. One important class of enzymes that has been the subject of intensive study is protein kinases.
"Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a variety of signal transduction processes within the cell (see, e.g., G. Hardie et al., The Protein Kinase Facts Book, I and II, Academic Press, San Diego, Calif., 1995). Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The kinases may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, lipids etc). Sequence motifs have been identified that generally correspond to each of these kinase families (see, e.g., S. K. Hanks et al., FASEB J., 1995, 9, 576-596; Knighton et al., Science 1991, 253, 407-414; Hiles et al., Cell, 1992, 70, 419-429; Kunz et al., Cell, 1993, 73, 585-596; Garcia-Bustos et al., EMBO J., 1994, 13, 2352-2361).
"In general, protein kinases mediate intracellular signaling by affecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway. These phosphorylation events act as molecular on/off switches that can modulate or regulate the target protein biological function. These phosphorylation events are ultimately triggered in response to a variety of extracellular and other stimuli. Examples of such stimuli include environmental and chemical stress signals (e.g., shock, heat shock, ultraviolet radiation, bacterial endotoxin, and H.sub.2O.sub.2), cytokines (e.g., interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-a), and growth factors (e.g., granulocyte macrophage-colony stimulating factor (GM-CSF), and fibroblast growth factor (FGF)). An extracellular stimulus may affect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis, survival and regulation of the cell cycle.
"Many diseases are associated with abnormal cellular responses triggered by protein kinase-mediated events as described above. These diseases include, but are not limited to, cancer, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cardiovascular diseases, allergies and asthma, Alzheimer's disease and hormone related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic agents.
"The Polo-like kinases (PLKs) belong to a family of serine/threonine kinases that are highly conserved across the species, ranging from yeast to man (reviewed in Lowery D M et al., Oncogene, 2005, 24, 248-259). The PLKs have multiple roles in cell cycle, including control of entry into and progression through mitosis.
"PLK1 is the best characterized of the PLK family members. PLK1 is widely expressed and is most abundant in tissues with a high mitotic index. Protein levels of PLK1 rise and peak in mitosis (see, e.g., R. Hamanaka et al., J. Biol. Chem., 1995, 270, 21086-21091). The reported substrates of PLK1 are all molecules that are known to regulate entry and progression through mitosis, and include CDC25C, cyclin B, p53, APC, BRCA2 and the proteasome. PLK1 is up-regulated in multiple cancer types and the expression levels correlate with severity of disease (see, e.g., Macmillan, J. C. et al., Ann. Surg. Oncol., 2001, 8, 729-740). PLK1 is an oncogene and can transform NIH-3T3 cells (see, e.g., M. R. Smith et al., Biochem. Biophys. Res. Commun., 1997, 234, 397-405). Depletion or inhibition of PLK1 by siRNA, antisense, microinjection of antibodies, or transfection of a dominant negative construct of PLK1 into cells, reduces proliferation and viability of tumor cells in vitro (see, e.g., R. Guan et al., Cancer Res., 2005, 65, 2698-2704; X. Liu et al., Proc. Nat'l. Acad. Sci. U.S.A., 2003, 100, 5789-5794, Y. Fan et al., World J. Gastroenterol., 2005, 11, 4596-4599; H. A. Lane et al., J. Cell Biol., 1996, 135, 1701-1713). Tumor cells that have been depleted of PLK1 have activated spindle checkpoints and defects in spindle formation, chromosome alignment and separation and cytokinesis. Loss in viability has been reported to be the result of an induction of apoptosis. In contrast, normal cells have been reported to maintain viability on depletion of PLK1. In vivo knock down of PLK1 by siRNA or the use of dominant negative constructs leads to growth inhibition or regression of tumors in xenograft models.
"PLK2 is mainly expressed during the G1 phase of the cell cycle and is localized to the centrosome in interphase cells. PLK2 knockout mice develop normally, are fertile and have normal survival rates, but are around 20% smaller than wild type mice. Cells from knockout animals progress through the cell cycle more slowly than in normal mice (see, e.g., S. Ma et al., Mol. Cell. Biol., 2003, 23, 6936-6943). Depletion of PLK2 by siRNA or transfection of kinase inactive mutants into cells blocks centriole duplication. Down-regulation of PLK2 also sensitizes tumor cells to taxol and promotes mitotic catastrophe, in part by suppression of the p53 response (see, e.g., T. F. Burns et al., Mol. Cell. Biol., 2003, 23, 5556-5571).
"PLK3 is expressed throughout the cell cycle and increases from G1 to mitosis. Expression is up-regulated in highly proliferating ovarian tumors and breast cancer and is associated with a worse prognosis (see, e.g., W. Weichert et al., Br. J. Cancer, 2004, 90, 815-821; W. Weichert et al., Virchows Arch, 2005, 446, 442-450). In addition to regulation of mitosis, PLK3 is believed to be involved in Golgi fragmentation during the cell cycle and in the DNA-damage response. Inhibition of PLK3 by dominant negative expression is reported to promote p53-independent apoptosis after DNA damage and suppresses colony formation by tumor cells (see, e.g., Z. Li et al., J. Biol. Chem., 2005, 280, 16843-16850).
"PLK4 is structurally more diverse from the other PLK family members. Depletion of this kinase causes apoptosis in cancer cells (see, e.g., J. Li et al., Neoplasia, 2005, 7, 312-323). PLK4 knockout mice arrest at E7.5 with a high fraction of cells in mitosis and partly segregated chromosomes (see, e.g., J. W. Hudson et al., Current Biology, 2001, 11, 441-446).
"Molecules of the protein kinase family have been implicated in tumor cell growth, proliferation and survival. Accordingly, there is a great need to develop compounds useful as inhibitors of protein kinases. The evidence implicating the PLK kinases as essential for cell division is strong. Blockade of the cell cycle is a clinically validated approach to inhibiting tumor cell proliferation and viability. It would therefore be desirable to develop compounds that are useful as inhibitors of the PLK family of protein kinases (e.g., PLK1, PLK2, PLK3 and PLK4), that would inhibit proliferation and reduce viability of tumor cells, particularly as there is a strong medical need to develop new treatments for cancer, including treatments that would be administered orally."
In addition to the background information obtained for this patent, NewsRx journalists also obtained the inventors' summary information for this patent: "In one aspect, the present invention provides compounds of Formula I shown and described herein, as well as their pharmaceutically acceptable salts.
"The compounds of this invention in general are potent inhibitors of protein kinases, such as PLKs (polo-like kinases), e.g., PLK1, PLK2, PLK3, or PLK4. Accordingly, these compounds and their pharmaceutically acceptable salts and compositions are useful for treating or preventing diseases, disorders, or medical conditions implicated or mediated by protein kinases such as PLKs (polo-like kinases), e.g., PLK1, PLK2, PLK3, or PLK4. Examples of such diseases or conditions include cancers, e.g., melanoma, myeloma, leukemia, lymphoma, neuroblastoma, colon cancer, breast cancer, gastric cancer, ovarian cancer, cervical cancer, lung cancer, central nervous system cancer, renal cancer, prostate cancer, bladder cancer, or pancreatic cancer.
"The compounds provided by this invention are also useful for the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors."
URL and more information on this patent, see: Charrier, Jean-Damien; Durrant, Steve. Protein Kinase Inhibitors. U.S. Patent Number 8618106, filed August 24, 2012, and published online on December 31, 2013. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=79&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3907&f=G&l=50&co1=AND&d=PTXT&s1=20131231.PD.&OS=ISD/20131231&RS=ISD/20131231
Keywords for this news article include: Vertex Pharmaceuticals Incorporated, Genetics, Oncology, p53 Gene, Apoptosis, Protein Kinases, Cancer Gene Therapy, Enzymes and Coenzymes, Biotechnology Companies, Biopharmaceutical Companies, Phosphotransferases (Alcohol Group Acceptor).
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
(c) 2014 Cancer Gene Therapy Week via NewsRx.com
http://www.4-traders.com/VERTEX-PHARMACEUTICALS-IN-11321/news/Vertex-Pharmaceuticals-Incorporated--Patent-Issued-for-Protein-Kinase-Inhibitors-17769313/
Earnings details
Generated nearly 450 million in hepatitis C revenues and royalties in the first half of this year
read here
http://www.earningsimpact.com/Transcript/82328/VRTX/Q2-2013-Earnings-Call
Covered 220 VRTX @ 76.77.
Profit: $200
Puts since the 23rd
If you're still short from last week; nice trade!
over the cliff:
Vertex's first quarter 2013 non-GAAP net income was $5.7 million, or $0.03 per diluted share. Vertex's non-GAAP net income for the first quarter of 2012 was $118.6 million, or $0.55 per diluted share.
Even forgetting GAAP they washed away $0.52 per quarter of non-GAAP EPS on falling revenues.
The decrease in the company's first quarter 2013 non-GAAP net income, compared to the first quarter of 2012, is primarily attributable to a decrease in total revenues, specifically decreased INCIVEK revenues due to fewer HCV patients initiating treatment.
Vertex's first quarter 2013 GAAP net loss was $(308.0) million, or $(1.43) per share. Vertex's GAAP net income for the first quarter of 2012 was $91.6 million, or $0.43 per diluted share, including $27.0 million in certain charges.
from as time-ROI perspective I probably should have taken the first drop to the support that is about to give out...
Alas the only ones that drop to fib level the same day they come up on the scans are the ones that I don't play for one reason or another (not wanting to have too much capital in puts is a very good reason!) e.g. WRLD
Agreed. I just didn't have the patience. Who knows, I may jump back in for another go.
Best of luck to you.
with the CFO's massive insider sales and a likely to disappoint 10Q coming, this is headed over a cliff. Check out the Seeking Alpha piece on it.
Been holding May 17th puts on it for a few days and up nicely. Target is a 61.8% fib retrace to $65.61...
Covered 220 VRTX @ 79.74.
8:36AM Vertex Pharm announces new data that showed high viral cure rates with a total of 12 and 24 weeks of telaprevir combination treatment among people with genotype 1 hepatitis C who have the IL28B CC genotype (VRTX) 83.53 : Co announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus (HCV) infection who have the IL28B CC genotype. In the CONCISE trial, telaprevir was administered twice daily in combination with pegylated-interferon and ribavirin. Of the 239 people in the study, 159 people completed 12 weeks of telaprevir combination treatment and had undetectable hepatitis C virus at week four of treatment (rapid viral response, or RVR) and were eligible to be randomized. One hundred seven people were randomized to receive no further treatment and 52 people were randomized to receive an additional 12 weeks of treatment with pegylated-interferon and ribavirin alone, for a total of 24 weeks of treatment. In the 12-week total treatment group, of the 85 people with data available at the time of the interim analysis, 87 percent (74/85) had undetectable hepatitis C virus 12 weeks after the end of treatment (SVR12). In the 24-week treatment group, of the 30 people with data available at the time of the interim analysis, 97 percent (29/30) achieved SVR12.
Figures my call was damn close - wasn't payin attention to this one today - should of stuck to my call and shorted @87.00 ohh well
Cheers.
All luck, though. If it blows past 85, I'll be stopped out. Deutsche has a $100 target, but I was hoping for more profit-taking rather than covering today.
Let's see how the dice fall.
Good call - I thought for sure it was going to be pushed past $87
Too soon - powerful lil turd lol
I'm looking also ;)
April 18, 2013 7:27 EDT VRTX Vertex spikes higher after reporting phase 2 study results
Shares of Vertex are shooting higher in the after hours session after the company reported results from a phase 2 study of VX-661 and ivacftor that showed statistically significant results. WHAT'S NEW: A phase 2 study of VX-661 and ivacftor in adult patients with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene showed statistically significant results. Patients in the 100mg and 150mg combination dose groups showed statistically significant mean relative improvements in lung function versus placebo, of 9% and 7.5%, respectively. In the study, Vertex said VX-661 was generally well-tolerated, both as monotherapy and in combination with ivacaftor. "This first study of VX-661 and ivacaftor provides further validation of the strategy of combining a corrector and potentiator to improve lung function in people with the most common type of cystic fibrosis," said Peter Mueller, Ph.D., chief scientific officer and executive VP of global research and development at Vertex. PRICE ACTION: Shares of Vertex are up $27.43, or 51.88%, to $80.30 in the after hours, a multi-year high for the stock, which is up more than 25% year-to-date.
Yup shorts are toasted!!!
Lol I agree - people must have screws loose to buy waaaaaay up here - shorts got fried on this bad boy
Up 51% @81.50 in AH.
Congrats longs. Don't get greedy and lock in the profit,
because after hitting the peak, it'll pull back 20 to 30% from the
top as they always do.
I missed the long play, so I'm looking to short eventually.
4:22PM Vertex Pharm announces initiation of pivotal Phase 3 program of VX-809 in combination with ivacaftor for the treatment of people with cystic fibrosis who have two copies of the F508del mutation (VRTX) 44.18 -0.68 : Co announced the initiation of a global pivotal Phase 3 development program for fixed-dose combinations of VX-809 (lumacaftor) and ivacaftor in people with cystic fibrosis (CF) who have two copies (homozygous) of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vertex plans to conduct two 24-week Phase 3 studies to support approval of the combination of VX-809 and ivacaftor in people with CF ages 12 and older. The studies, TRAFFIC and TRANSPORT, will each include two treatment groups that will evaluate VX-809 (600mg QD or 400mg q12h) in combination with ivacaftor (250mg q12h) compared to a placebo group. Vertex expects to obtain 24-week safety and efficacy data from both studies and to submit a New Drug Application to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency, pending study results.
Co also plans to conduct a pharmacokinetics and safety study to evaluate VX-809 in combination with ivacaftor in children with CF ages 6 to 11 who have two copies of the F508del mutation. The company expects to use the data from this study for subsequent registration in children ages 6 to 11 in the United States and is continuing discussions with European regulatory agencies for patients in this age group.
Orphan Drugs & Value Propositions: Randy Explains
Make a comment
By Ed Silverman // January 17th, 2013 // 11:16 am
Earlier this month, NPS Pharmaceuticals announced that the price for its Gattex treatment for short-bowel syndrome would cost $295,000 a year, roughly three times what Wall Street had expected. This marked the fourth time in the past year that an orphan drug was approved and the price per patient was set at more than $200,000 annually. The move highlighted a growing debate about the calculations used for developing new medications designed for small patient populations and the ability of the healthcare system to afford these treatments and accommodate patients. We spoke with Randy Vogenberg, a principal at the Bentelligence consulting firm, which specializes in benefits consulting and strategic decision making, about the implications for drug makers and payers…
Pharmalot: Why are we seeing this kind of pricing?
Vogenberg: I think part of the reason is that we’re dealing with smaller patient populations than in the past and that’s the typical situation. There are hundreds instead of however many tens of thousands of patients and then we’re spreading cost among a smaller group. So unit costs rise dramatically. And there’s a Catch 22 around pricing – which is a little unique around specialty (drugs). You have a smaller number (of patients) and charging a higher price, so there’s a higher percentage of patients who can’t afford it. This means there’s greater need for unrestricted grants and patient assistant programs. So as a company, you end up paying more for your own product than in the older, traditional marketplace.
more...
http://www.biotechinvestorsnetwork.com/#!featured-article/c17ob
Might be the turn around here ?
Vertex Reschedules its Third Quarter 2012 Financial Results Conference Call and Webcast Due to Hurricane Sandy
-Company to announce third quarter financial results on Thursday, November 1, 2012-
Press Release: Vertex Pharmaceuticals Incorporated – Mon, Oct 29, 2012 9:11 AM EDT.. .
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
As a result of the effects of Hurricane Sandy and the related closure of the financial markets, Vertex Pharmaceuticals Incorporated (VRTX) today announced that it has rescheduled its third quarter 2012 earnings press release and conference call, which were originally scheduled for today, Monday, October 29. Vertex will now announce its third quarter 2012 financial results on Thursday, November 1, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT on Thursday.
The conference call will be webcast live and a link to the webcast may be accessed from the ‘Events & Presentations' page of Vertex's website at www.vrtx.com. A replay of the conference call and webcast will be archived on the company's website until November 15, 2012. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Vertex
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, Mass., we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada. Today, Vertex has more than 2,000 employees around the world, and for three years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. Vertex's press releases are available at www.vrtx.com.
VRTX – GEN
4:00PM Vertex Pharm announces positive results from viral kinetic study of the nucleotide analogue ALS-2200 in people with hepatitis C (VRTX) 49.96 +0.64 : Co announced positive results from a viral kinetic study of the nucleotide analogue ALS-2200 for the treatment of hepatitis C. There was a median 4.54 log10 reduction in hepatitis C virus (HCV) RNA in people with genotype 1 chronic hepatitis C who were new to treatment (n=8) after seven days of dosing with 200 mg of ALS-2200 once daily. ALS-2200 was well-tolerated in this study, and no patients discontinued due to adverse events. Based on these data, Vertex plans to begin Phase 2 studies this year of 12-week all-oral regimens including ALS-2200 in people with genotype 1 hepatitis C, pending discussions with regulatory agencies.
Gift ?? They really love to hand out gifts.
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320&type=&dateb=&owner=include&start=0&count=40
Here’s your answer: #msg-77070399, #msg-77070752.
AH - ouch !!! $52.25
VRTX has now achieved one of its main business goals: #msg-75281415.
7:30AM Vertex Pharm: interim data from Phase 2 combination study of VX-809 and KALYDECO (ivacaftor) showed 'significant' improvements in lung function (FEV1) in people with cystic fibrosis who have two copies of the F508del mutation (VRTX) 37.41 : Co announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del. A planned interim analysis was conducted after approximately half of the study patients had completed 56 days of treatment. Today's results are based on data from 37 homozygous F508del patients who completed treatment in the 56-day study and 11 patients with one or two copies of the F508del mutation who received placebo. There was a statistically significant improvement in lung function (absolute change in percent predicted FEV1) across the combined treatment groups relative to baseline compared to placebo (p=0.002). Of those who received VX-809 and KALYDECO (250mg, q12h), approximately 46 percent (17/37) experienced an absolute improvement from baseline to Day 56 in lung function of 5 percentage points or more, and approximately 30 percent (11/37) experienced an absolute improvement from baseline to Day 56 of 10 percentage points or more. None of the patients treated with placebo (0/11) achieved a 5-percentage point or more improvement from baseline to Day 56 in lung function. Most adverse events were mild or moderate in severity and comparable between treatment and placebo groups. The study is ongoing and complete data, including statistical analyses for all patient groups, will be available in mid-2012. Stock to resume trading at 7:50.
Vertex Pharm VRTX UBS Neutral $35 » $44
Read more: http://www.breifing.com/investor/calendars/upgrades-downgrades/#ixzz1qQSwyocl
Vertex Pharm reports data from Phase 2 Study of an INCIVEK combination regimen showed 74% of people co-infected with hepatitis C and HIV had undetectable hepatitis C virus 12 weeks after treatment ended (SVR12) (VRTX) 39.91 -0.52 : Co announced interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with genotype 1 hepatitis C virus and human immunodeficiency virus (HIV). Data showed 74 percent (28/38) of patients who were treated with INCIVEK combination therapy had undetectable hepatitis C virus (HCV RNA) 12 weeks after the end of all study treatment (SVR12) compared to 45 percent (10/22) who were treated with pegylated-interferon and ribavirin alone. INCIVEK was well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens.
~ $VRTX ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $VRTX ~ Earnings expected on Thursday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=VRTX&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=VRTX&p=W&b=3&g=0&id=p54550695994
~ Barchart: http://barchart.com/quotes/stocks/VRTX?
~ OTC Markets: http://www.otcmarkets.com/stock/VRTX/company-info
~ Google Finance: http://www.google.com/finance?q=VRTX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=VRTX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=VRTX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=VRTX
Finviz: http://finviz.com/quote.ashx?t=VRTX
~ BusyStock: http://busystock.com/i.php?s=VRTX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=VRTX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=VRTX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=VRTX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=VRTX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=VRTX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=VRTX
~ MarketWatch: http://www.marketwatch.com/investing/stock/VRTX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=VRTX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=VRTX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=VRTX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=VRTX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=VRTX&size=l&frequency=60&color=g
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
Leerink cut sales estimates.
Followers
|
31
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
185
|
Created
|
04/27/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |